X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Sun Pharma: 4Q hiccups - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • Jun 4, 2002

    Sun Pharma: 4Q hiccups

    Sun Pharma has ended FY02 with 22% growth in sales driven mainly by domestic formulation sales. Operating margins jumped by 120 basis points to 26%. However, growth seems to have slowed down considering the fourth quarter numbers, which recorded a growth of 10% in topline.

    (Rs m) 4QFY01 4QFY02 % change FY01 FY02 % change
    Sales 1,634 1,803 10.4% 6,114 7,477 22.3%
    Other Income 12 44 280.2% 97 112 15.8%
    Expenditure 1,267 1,354 6.8% 4,603 5,543 20.4%
    Operating Profit (EBDIT) 366 449 22.6% 1,512 1,934 27.9%
    Operating Profit Margin (%) 22.4% 24.9%   24.7% 25.9%  
    Interest - - - -
    Depreciation 39 50 27.9% 162 174 7.2%
    Profit before Tax 339 443 30.8% 1,446 1,872 29.4%
    Other Adjustments -   - -26.4
    Tax 25.7 39.3 52.9% 94.5 160 69.3%
    Profit after Tax/(Loss) 313 404 29.0% 1,352 1,686 24.7%
    Net profit margin (%) 19.2% 22.4%   22.1% 22.5%  
    No. of Shares (eoy) (m) 46.8 46.8   46.8 46.8  
    Diluted Earnings per share 26.8 34.5   28.9 36.0  
    P/E (at current price)   16.4     15.8  

    The positive highlight of the quarter was continuing strong growth in the domestic formulations segment which grew by 24% from Rs 891 m to Rs 1.1 bn. Bulk exports grew marginally by 3% to Rs 269 m, but domestic bulk saw a negative growth of 9% to Rs 341 m. The key reason for this is the discontinuation of the Cephalosporins business. The company is expected to further prune Cephalosporin bulk business to the tune of Rs 300 m. The disappointing part of the results was a dismal performance in formulations exports. However, the company is confident of achieving 30% growth in this segment going forward. Further, results were also impacted due to Pradeep Drugs merger into Sun, which incurred a loss of Rs 10 m.

    Meanwhile, Caraco, Sun's US subsidiary, inched forward to break even, reducing its YoY operating loss from US $ 1.2 m to a marginal US $ 0.2 m. Caraco is likely to file 5 ANDAs in the current year and Sun will file an additional 4 ANDAs from India. Over the last six months, Caraco has received 4 drug approvals and is targeting 5 more in the current year. However, each approval individually is not very attractive. Additionally, Sun Pharma is expected to file 4 ANDA's on its own. The bulk drugs for these ANDA's are likely to be supplied from Sun, as the company's manufacturing facilities now enjoy neccessary FDA approvals. Operating margins on a consolidated basis are expected to improve on account of this.

    At the current market price of Rs 568, the stock is trading at 16x its FY02 earnings. Though valuations are at a discount to its peers, the same could be expected to improve only on further clarity on its international business. Considering the product portfolio of Caraco, we expect Caraco to take another 5-6 months time before it achieves breakeven.

     

     

    Equitymaster requests your view! Post a comment on "Sun Pharma: 4Q hiccups ". Click here!

      
     

    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

    May 30, 2017

    US markets decline while other geographies grow in the quarter.

    Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

    Mar 11, 2017

    Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    More Views on News

    Most Popular

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    The Most Profitable Investment in the History of the World(Vivek Kaul's Diary)

    Aug 8, 2017

    'Yes, it looks like a bubble. And, yes, it's like buying a lottery ticket. But there's something happening that has never happened before. It's an evolutionary leap in money itself.'

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    Bitcoin Continues Stellar Rise(Chart Of The Day)

    Aug 10, 2017

    Bitcoin hits an all-time high, is there more upside left?

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
     

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    SUN PHARMA SHARE PRICE


    Aug 21, 2017 (Close)

    TRACK SUN PHARMA

    • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks

    SUN PHARMA - GLENMARK PHARMA COMPARISON

    Compare Company With Charts

    COMPARE SUN PHARMA WITH

    MARKET STATS